



**ANITA VARMA, PARTNER,
ROPES & GRAY LLP (US)**

Anita has over 20 years of experience in intellectual property law as a lawyer and as a Patent Examiner at the United States Patent and Trademark Office (USPTO). Her experience as a Patent Examiner provides unique insights into the workings of the US PTO and as a UK Solicitor she is qualified to practice before the European Patent Office. Anita focuses her practice on developing, analyzing, and managing patent portfolios in diverse areas of technology for life sciences companies. She leverages this broad patent experience to counsel clients on transactional matters in connection with financial investments, mergers and acquisitions, and collaborations. Anita combines her patent experience with an understanding of regulatory exclusivities to help clients evaluate target portfolios and conduct worldwide due diligence assessments. She has conducted numerous pre-litigation assessments and rendered opinions regarding patentability, validity, non-infringement, freedom-to-use, Orange Book listing and delisting matters, and advised clients regarding the follow-on biologics legislation.

Representative Clients and Matters

- Representative Litigations Promote Innovation, LLC v. Intendis, Inc. (Eastern District of Texas), 2:10-cv-00247-TJW.
- Novartis Vaccines v. **Wyeth** (Eastern District of Texas), 2:08-cv-00067-TJW-CE.
- **Genetics Institute** v. Novartis Vaccines (District of Delaware), 1:08-cv-00290-SL.
- Abbott Laboratories et al. v. **Bayer Healthcare LLC** (District of Massachusetts), 09-CV-40002-FDS.
- Novartis Vaccines et al v. **Bayer Healthcare LLC** (Eastern District of Texas), 2:08-cv-00068-TJW.
- Representative Transactions Represented a private equity client in their bid to acquire a large European specialty pharmaceutical company. This included reviewing the target company's worldwide portfolio of about 1500 patents, analyzing seven ongoing ANDA litigations and conducting a competitive patent landscape analysis.
- Represented a pharmaceutical company in conducting due diligence on a portfolio covering a new formulation of an existing drug to structure a Supply and Manufacturing Agreement.
- Represented a pharmaceutical company to conduct freedom to operate studies on at least 100 drug products to be marketed in emerging markets such as Mexico, Brazil, Argentina, Malaysia, South

Africa etc. We considered patent assessments and any available regulatory exclusivities to determine the extent and duration of patent and regulatory coverage.

- Represents a pharmaceutical company in conducting a world-wide pre-litigation assessment of their patent portfolios covering therapeutic products in clinical trials.

Presentations & Speeches

- C5's 8th International Forum on Freedom to Operate, May 18-19th, 2011: "The Impact of US Case Law Developments on FTO Analysis."
- NACUA 2010 Annual Conference, November 12th, 2010: "Patent Eligibility Following Bilski."
- Panelist, Boston Bar Association and Boston Patent Law Association, April 29th, 2010: "The Biosimilar Regulatory Pathway: Statutory Framework & IP Implications."
- American Conference Institute's 7th National Conference on Life Sciences IP Due Diligence, January 20-21, 2010: "Freedom-to-Operate."
- ACI Biotech Patent Conference, October 1st, 2009: "Master Class on Drafting Successful Patent Applications for Biotechnology Related Inventions."

Memberships

- American Bar Association
- Maryland Bar Association
- Massachusetts Bar Association
- New Jersey Bar Association

Bar Admissions

- Maryland
- New Jersey
- Massachusetts
- U.S. Patent and Trademark Office
- England and Wales, Solicitor

Education

- 1996, JD, Georgetown University Law Center
- BS (Chemistry), Jiwaji University
- MS (Chemistry), Jiwaji University
- MS (Biochemistry), American University